Editorial abstract cover illustrating Oral GLP-1s in the UAE: Researching Prescriber and Patient Uptake of Orforglipron
    Market Research

    A daily weight-loss pill is not yet a prescription count — Oral GLP-1 UAE market research after the 2026 approvals

    I
    Ivona GunjovaGlobal Research Manager
    16 Oct 2026
    10 min
    United Arab Emirates
    ObesityGLP-1Oral GLP-1OrforglipronFoundayoUAEMarket AccessPrimary Research
    Share:

    Oral GLP-1 UAE market research starts when a regulator says a tablet may be sold. It does not start from a national obesity percentage. GLP-1 drugs copy a gut hormone. Some are weekly injections. The new question is the tablet. This page sits beside the UAE obesity market and the healthcare market research hub. Abu Dhabi’s payer rules are a separate file on Thiqa obesity reimbursement. Qatar is a different country, covered on GLP-1 research in Qatar.

    What was approved, and by whom

    The Emirates Drug Establishment, EDE, is the federal medicines authority. Its own site says it was established on 29 September 2023 (Emirates Drug Establishment). The UAE government portal lists the health regulators and the split between the ministry, the emirate health authorities, and the drug establishment (UAE government portal). The Ministry of Health and Prevention has transferred 44 core pharmaceutical services to EDE (Ministry of Health and Prevention). Pricing and registration questions now start at EDE. A ministry page from an earlier year is not the current filing desk.

    Orforglipron UAE approval was reported on 3 April 2026. Orforglipron is the generic name. Foundayo is Eli Lilly’s brand. The Emirates News Agency said EDE had approved a new oral obesity treatment and described the UAE as the second country to do so (Emirates News Agency, 3 April 2026). ZAWYA carried that agency copy and described a shift away from injections (ZAWYA, 3 April 2026). Gulf News reported a daily weight-loss pill with no injections (Gulf News, 3 April 2026). On 4 April 2026, The National wrote that the UAE-approved daily pill was to be made available the next month (The National, 4 April 2026). That is what the paper said in April. This page does not turn that sentence into a later sales figure.

    Timeline of 2026 oral GLP-1 dates: US approval on 1 April, UAE approval reported on 3 April, and a Wegovy pill launch reported on 3 June
    The US regulator approved Foundayo on 1 April 2026. Emirates News Agency reported UAE approval on 3 April 2026. Novo Nordisk reported a Wegovy pill launch in the UAE on 3 June 2026. Approval is not a count of prescriptions.

    The US Food and Drug Administration approved the same new molecule on 1 April 2026, and called it the first new molecular entity cleared under its National Priority Voucher program (US FDA, 1 April 2026). A new molecular entity is a drug whose active ingredient has not been approved before. Lilly’s own announcement the same day called Foundayo the only GLP-1 pill for weight loss that can be taken at any time of day, without food or water restrictions (Eli Lilly, 1 April 2026). The US prescribing information is titled FOUNDAYO (orforglipron) tablets, with initial US approval in 2026 and application number NDA 220934 (US prescribing information). A US label is not a UAE price, and it is not a UAE prescription count.

    On 5 August 2026 The National published a further article on new UAE-approved weight-loss pills (The National, 5 August 2026). Use it as a later news report. Do not read the headline as a measured share of patients.

    Two pills, two studies

    Foundayo is not the only oral GLP-1 in the news. On 3 June 2026 Novo Nordisk said it had launched the Wegovy pill in the UAE (Novo Nordisk, via ZAWYA, 3 June 2026). CNBC described that launch as the first one outside the United States (CNBC, 3 June 2026). Wegovy’s tablet uses semaglutide, a different molecule from orforglipron. Khaleej Times wrote on 18 June 2026 about prices, doses and first-time interest in the Wegovy pill (Khaleej Times, 18 June 2026). This briefing does not copy a price the article does not put in the reference line. Ask the pharmacy what was actually charged.

    The clinical papers are also separate. ATTAIN-1 is a New England Journal of Medicine paper on orforglipron for obesity, registered as NCT05869903 (ATTAIN-1). ATTAIN-2, in The Lancet in 2025, studied orforglipron for obesity in people who also have type 2 diabetes (ATTAIN-2). Lilly’s medical site asks how Foundayo compared with placebo in ATTAIN-2 (Lilly Medical). The reference line does not carry a percentage for that comparison, so this page will not invent one.

    Oral semaglutide has its own trial. OASIS 4, also in the New England Journal of Medicine in 2025, studied a 25 mg tablet in adults with overweight or obesity (OASIS 4). On 17 September 2025 Novo Nordisk said that 25 mg dose delivered 16.6 percent weight loss in the published study (Novo Nordisk, 17 September 2025). That sentence belongs to oral semaglutide. It is not an orforglipron result, and the two trials are not a head-to-head.

    Chart reminding readers that Foundayo and oral semaglutide trials are separate studies
    These are separate studies, not a head-to-head. Novo Nordisk said on 17 September 2025 that oral semaglutide 25 mg delivered 16.6% weight loss in a published obesity study. Do not paste that figure onto orforglipron.

    A US paper in JAMA Network Open studied how often adults with overweight or obesity stop and restart GLP-1 drugs (JAMA Network Open, 2025). The reference line does not give a percentage, and the patients were in the United States. Do not paste a US stopping rate onto a UAE clinic.

    Obesity figures that do not match

    Quote each obesity figure with its survey and its year. They are not one time series.

    • The Ministry of Health and Prevention’s National Health and Nutrition Survey for 2024–2025 measured adult obesity at 22.4 percent (Ministry of Health and Prevention). The Emirates News Agency released that survey on 6 January 2026 (Emirates News Agency, 6 January 2026). Gulf News covered the same survey’s findings on smoking and exercise (Gulf News).
    • The ministry’s National Health Survey for 2017–2018 measured 4,971 adults and found 27.8 percent obese (National Health Survey 2017–2018). That is an earlier survey, with its own method.
    • The World Health Organization’s indicator for adult obesity uses a body mass index of 30 or above and is age-standardised (World Health Organization). Our World in Data, using that indicator, puts the UAE figure for 2024 at 31.6 percent (Our World in Data). Age-standardised means the rate is adjusted so a young country and an older country can be compared. A clinic does not treat an age-standardised person.
    Bar chart of separate UAE adult obesity figures from MoHAP surveys and a WHO age-standardised estimate
    MoHAP’s 2024–25 survey measured adult obesity at 22.4%. The 2017–18 survey measured 27.8% of 4,971 adults. A WHO age-standardised estimate for 2024 is 31.6%. The methods differ. Do not average them.

    Do not subtract 27.8 from 31.6, or 22.4 from 27.8, and call the gap a rise or a fall. The methods differ. None of these rates is the number of people who will be prescribed a tablet.

    Diabetes figures are a second topic. The International Diabetes Federation says 1,274.2 thousand adults aged 20 to 79 in the UAE had diabetes in 2024, a prevalence of 20.7 percent, with 64.0 percent undiagnosed (International Diabetes Federation). Our World in Data repeats the 20.7 percent for 2024 (Our World in Data, diabetes). Undiagnosed means the atlas’s estimate of people who have diabetes and do not know it. It is not a queue for a weight-loss pill. ATTAIN-2 is the study that enrolled people with both obesity and type 2 diabetes. The atlas is not that study.

    The population frame is smaller than a “Gulf” slide and larger than a clinic. The Federal Competitiveness and Statistics Centre puts the 2024 population at about 11.29 million (Federal statistics centre). Gulf News printed the centre’s count as 11,294,243 residents in 2024, against 10,678,556 in 2023 (Gulf News). Those two sentences are the same estimate, one of them rounded. They are not the number of adults with obesity, and they are not the number who will pay for a pill.

    Registration is not a paid prescription

    An EDE approval answers one question: the product may be registered. It does not say a pharmacy has stock, a doctor has written the first prescription, a patient is still taking it three months later, or an insurer is paying. Keep those steps apart.

    Five-step oral GLP-1 UAE uptake funnel from EDE registration through stocking, initiation, persistence and reimbursement
    Five layers a 2026 orforglipron UAE brief has to keep separate: EDE registration, pharmacy stocking, first prescription, continuation, and which wallet pays. A launch announcement fills only the first layer.

    Grand View Research, 6Wresearch and Ken Research publish UAE and Gulf obesity outlooks that often appear for this search. They are category pages. They do not record which tablet a Dubai endocrinologist started last week. Use them as background. Commission the prescriber study for the decision.

    Questions to put in the brief

    Write one decision at the top of the brief. It might be a forecast split between tablet and injection, a brand choice inside the tablet class, or a plan for clinics that take cash rather than insurance.

    Checklist of seven workstreams oral GLP-1 UAE market research should cover after Foundayo
    Seven workstreams: oral versus injectable mix, new starts versus switchers, brand within oral, channel and nationality, titration and GI drop-off, persistence, and prescriber setting.
    • Which product. Ask about orforglipron and oral semaglutide in separate questions. Do not let a respondent “pick a pill” and then blend the answers.
    • Which event the respondent means. US approval was 1 April 2026. The UAE approval was reported on 3 April 2026. The Wegovy pill launch was reported on 3 June 2026. The National’s April line about the next month is an April statement.
    • New start or switch. A patient leaving an injection is not the same as a patient starting treatment for the first time.
    • Who pays. Abu Dhabi’s Thiqa rules are not Dubai’s rules. Ask which wallet, in which emirate.
    • Which obesity number the forecast uses. 22.4 percent, 27.8 percent and 31.6 percent cannot sit in one cell. Name the source.
    • What “still taking it” means. The US discontinuation paper is not a UAE rate. Measure continuation in the UAE sample.

    Report results as a share of patients treated, by product and emirate. Ask for Arabic and English instruments. Ask the agency to show the date on every official figure.

    How to brief BioNixus

    BioNixus is a primary market research firm for pharmaceutical, medical device and healthcare companies. It was founded in 2012. Custom studies are usually priced at $10k–$60k. The firm has 40 client reviews on its public profiles. The line “Guaranteed in writing” covers the agreed scope and timeline. It does not cover what the interviews will find.

    Leadership offices are in Sheridan, Wyoming, London, and Sheikh Zayed, Giza. Field offices are in Dubai, Al Khobar, and Salmiya, Kuwait. São Paulo is a field office for LATAM.

    To brief an oral GLP-1 study, use the contact form or email admin@bionixus.com. Say which pill, which emirate and which decision the study has to answer.

    References

    1. Emirates News Agency (WAM). Emirates Drug Establishment approves new oral obesity treatment, positioning UAE as second country globally. Dubai, 3 April 2026. Source (accessed 16 October 2026).
    2. ZAWYA, carrying WAM. Emirates Drug Establishment approves oral obesity treatment, marking shift away from injections. 3 April 2026. Source (accessed 16 October 2026).
    3. Gulf News. New daily weight-loss pill approved in UAE, no injections needed. 3 April 2026. Source (accessed 16 October 2026).
    4. The National. UAE-approved daily weight loss pill to be made available next month. 4 April 2026. Source (accessed 16 October 2026).
    5. U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. 1 April 2026. Source (accessed 16 October 2026).
    6. Eli Lilly and Company. FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. 1 April 2026. Source (accessed 16 October 2026).
    7. U.S. Food and Drug Administration. FOUNDAYO (orforglipron) tablets, for oral use. Prescribing information. Initial U.S. approval 2026. NDA 220934. Source (accessed 16 October 2026).
    8. ATTAIN-1 investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. NCT05869903. Source (accessed 16 October 2026).
    9. Horn DB, Ryan DH, Giljanovic Kis S, et al. Orforglipron for obesity in people with type 2 diabetes (ATTAIN-2). Lancet. 2025;406(10522):2927–2944. Source (accessed 16 October 2026).
    10. Lilly Medical. In ATTAIN-2, how did Foundayo™ (orforglipron) compare with placebo in adults with obesity or overweight and type 2 diabetes? Source (accessed 16 October 2026).
    11. Emirates Drug Establishment. Home. Established 29 September 2023 as the federal medicines authority. Source (accessed 16 October 2026).
    12. Ministry of Health and Prevention, UAE. Ministry of Health and Prevention transfer key services to Emirates Drug Establishment. 44 core pharmaceutical-sector services. Source (accessed 16 October 2026).
    13. UAE Government portal (u.ae). Health regulatory authorities. Source (accessed 16 October 2026).
    14. Ministry of Health and Prevention, UAE. MoHAP Publishes Landmark National Health Survey Showing Population Health Progress. National Health and Nutrition Survey 2024–2025; adult obesity 22.4%. Source (accessed 16 October 2026).
    15. Emirates News Agency (WAM). MoHAP releases National Health and Nutrition Survey 2024-2025. 6 January 2026. Source (accessed 16 October 2026).
    16. Gulf News. UAE population smokes less and exercises more, health data shows. National Health and Nutrition Survey 2024–2025 coverage. Source (accessed 16 October 2026).
    17. Ministry of Health and Prevention, UAE. National Health Survey Report 2017–2018. STEPS; 4,971 measured adults; 27.8% obese. Source (accessed 16 October 2026).
    18. Our World in Data, from WHO GHO (2026). UAE adult obesity 2024: 31.6% (age-standardised, both sexes, BMI ≥ 30). Source (accessed 16 October 2026).
    19. World Health Organization. GHO indicator NCD_BMI_30A: adult obesity, BMI ≥ 30, age-standardised. Source (accessed 16 October 2026).
    20. International Diabetes Federation. IDF Diabetes Atlas: United Arab Emirates. Adults 20–79 with diabetes in 2024: 1,274.2 thousand; prevalence 20.7%; undiagnosed 64.0%. Source (accessed 16 October 2026).
    21. Our World in Data, from International Diabetes Federation via World Bank (2026). UAE diabetes prevalence 2024: 20.7%. Source (accessed 16 October 2026).
    22. Federal Competitiveness and Statistics Centre. Unified UAE Numbers (English). Population 2024: about 11.29 million. Source (accessed 16 October 2026).
    23. Gulf News. UAE population hits 11.3 million in 2024. FCSC: 11,294,243 residents versus 10,678,556 in 2023. Source (accessed 16 October 2026).
    24. Novo Nordisk (via ZAWYA). Wegovy pill launches in the UAE as Novo Nordisk expands global access to obesity care. 3 June 2026. Source (accessed 16 October 2026).
    25. CNBC. Novo Nordisk rolls out Wegovy pill in the UAE — testing appetite outside the U.S. with first global launch. 3 June 2026. Source (accessed 16 October 2026).
    26. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393:1077–1087. OASIS 4. Source (accessed 16 October 2026).
    27. Novo Nordisk. Oral semaglutide 25 mg delivered 16.6% weight loss in people with obesity in a newly published study. 17 September 2025. Source (accessed 16 October 2026).
    28. Khaleej Times. Wegovy pill in UAE: Prices, doses and why first-time users are showing interest. 18 June 2026. Source (accessed 16 October 2026).
    29. Webster N. New UAE-approved weight loss pills deliver health boost for patients. The National. 5 August 2026. Source (accessed 16 October 2026).
    30. Rodriguez PJ, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349. Source (accessed 16 October 2026).
    31. Grand View Research. UAE / GCC obesity and weight-management report pages that rank for oral GLP-1 UAE queries. (accessed 16 October 2026).
    32. 6Wresearch. UAE and GCC obesity treatment and anti-obesity drug report pages. (accessed 16 October 2026).
    33. Ken Research. GCC / UAE obesity and weight-management report pages that appear for the same queries. (accessed 16 October 2026).

    Explore related research

    For deeper regional insight, explore our healthcare market research framework and country coverage.

    Explore BioNixus capabilities & hubs

    Directory of every indexed marketing destination — GCC and MENA research pages, localized hubs, methodologies, pharmaceutical directories, reports, global websites, insights, case studies, methodology, and Arabic coverage. Prefer this index over generic “related” lists for full-site context.

    12 groups · 265 URLs

    Full structured sitemap
    Home & language hubsLocalized entry points for BioNixus.5
    Company, trust & methodologyAbout, contact, compliance, and how we work.28
    Core servicesQuantitative, qualitative, access, intelligence, trials, KOL.3
    Healthcare market research hubCountries, cities, therapy areas, and research modules.57
    GCC, MENA & specialty programsPillar landings, alternatives, and deep-dive reports.36
    Pharmaceutical company directoriesCountry-level industry snapshots.9
    Healthcare & devices market reportsGCC and country medical market briefs.1
    Blog & insightsEditorial briefs, guides, and regional analysis.80
    Case studiesSelected client evidence and programme outcomes.5
    Portfolio & conferenceStrategic portfolio deck and event pages.2
    Localized pagesMarket access, contacts, and market research by locale.6
    Additional pagesSupporting URLs and tooling.33

    FAQFrequently asked questions

    What is oral GLP-1 UAE market research?
    It is commissioned research on who prescribes a daily weight-loss tablet in the UAE, who keeps taking it, and who pays. An approval notice is not that study.
    Did the Emirates Drug Establishment approve orforglipron?
    The Emirates News Agency reported on 3 April 2026 that the Establishment had approved a new oral obesity treatment, and described the UAE as the second country to do so. Lilly’s brand name for orforglipron is Foundayo. The US regulator had approved it two days earlier.
    When did newspapers say the pill would be available?
    On 4 April 2026 The National wrote that the UAE-approved daily pill was to be made available the next month. That is the paper’s April statement. It is not a later count of prescriptions.
    How does Foundayo compare with the Wegovy pill?
    They are different molecules. Novo Nordisk and CNBC reported a Wegovy pill launch in the UAE on 3 June 2026. Novo said on 17 September 2025 that oral semaglutide 25 mg delivered 16.6 percent weight loss in its published study. That figure is not an orforglipron result. The trials are not a head-to-head.
    How common is obesity in the UAE?
    It depends which file you open. The 2024–25 ministry survey measured 22.4 percent. The 2017–18 survey measured 27.8 percent of 4,971 adults. A WHO age-standardised estimate for 2024 is 31.6 percent. Do not average them.
    Does an EDE approval mean Thiqa will pay?
    No. Registration, pharmacy stock, the first prescription, continuation and the payer are separate questions. Abu Dhabi’s Thiqa rules are a different document from an EDE approval.
    What does a BioNixus study cost, and what is guaranteed?
    Custom studies are usually $10k–$60k. Guaranteed in writing covers the agreed scope and timeline. It does not cover what the interviews will find. The firm has 40 client reviews on its public profiles.

    Expert Consultation

    Planning oral GLP-1 or orforglipron research in the UAE?

    Tell us the prescribing decision you need to make. BioNixus scopes the study around that decision. Custom work is usually $10k–$60k.

    Talk to BioNixus
    I

    Research Author

    Ivona Gunjova

    Global Research Manager

    Related Articles

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.
    Healthcare Market Research
    Saudi Arabia15 Nov 2026

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.

    Syndicated Saudi diabetes reports size the category. They do not show which hospital is switching. Here is what primary research still has to answer.

    Read article
    ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant
    Healthcare Market Research
    UAE11 Nov 2026

    ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant

    ADCAN Pharma and M42 signed an MoU on UAE oncology manufacturing, an ADC registration and IROS clinical trials. What is confirmed and what to research.

    Read article
    The UAE Has Cleared Lilly's Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now
    Healthcare Market Research
    UAE10 Nov 2026

    The UAE Has Cleared Lilly's Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now

    The UAE approved Lilly's oral GLP-1 Foundayo for type 2 diabetes on 6 Nov 2026. What is confirmed, what is not, and what launch teams should research.

    Read article
    Novo Nordisk Gives Ozempic a Second Name, Plosbrio, and Hands It to Abbott in Asia Pacific
    Healthcare Market Research
    Singapore / Asia Pacific9 Nov 2026

    Novo Nordisk Gives Ozempic a Second Name, Plosbrio, and Hands It to Abbott in Asia Pacific

    Abbott will sell Plosbrio, Novo Nordisk's second semaglutide brand, in Singapore and Asia Pacific for type 2 diabetes. What is confirmed, what is not, and what it means for GLP-1 markets.

    Read article
    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One
    Healthcare Market Research
    Saudi Arabia5 Nov 2026

    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One

    Avalon Pharma licensed a generic Mounjaro KwikPen (tirzepatide) from OneSource for Saudi Arabia and MENA. What it means for GLP-1 and obesity teams.

    Read article

    Planning research in United Arab Emirates?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.